文献速递艾滋病与性传播感染

CTL表位特异性在HIV治愈研究中的新兴作用

The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts.
PubMed 文献 · J Infect Dis · 2021-01-01

本综述讨论细胞毒性T淋巴细胞(CTL)在HIV治愈努力中的新兴作用,重点强调表位特异性。近期研究显示,成功体内控制病毒源于特异性靶向HIV蛋白质组中适应度受限、突变 resistant 的区域。作者将这些新见解与既往HIV及其他病毒控制模型的观察相结合,并阐述其向治疗性疫苗的转化。

要点

  • CTL可持久抑制部分患者停药后病毒反弹。
  • 表位特异性靶向适应度受限、突变 resistant 区域是关键。
  • 这些见解可指导治疗性疫苗的转化。

核心结论

  • CTL的表位特异性,尤其是靶向适应度受限、突变 resistant 的HIV蛋白质组区域,在HIV治愈中具有新兴重要作用。

研究设计与样本

  • 综述类文章,检索范围未在摘要中报告。

主要发现

  • 部分个体中CTL可在无治疗情况下持久抑制病毒出生长。
  • 近期研究表明成功体内控制病毒源于特异性靶向适应度受限、突变 resistant 的HIV蛋白质组区域。

临床怎么用

  • 将CTL表位特异性见解转化为治疗性疫苗是临床转化方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of an effective human immunodeficiency virus (HIV) cure is a critical global health priority. A major obstacle to this effort is the establishment of a latent reservoir of HIV infected cells, which necessitates lifelong therapy, causing both logistical and adherence burdens for infected individuals. However, in a subset of these individuals, cytotoxic T lymphocytes (CTLs) can durably suppress viral outgrowth in the absence of therapy, providing a path towards a viable HIV cure. In this review, we discuss the emerging role that CTLs have in HIV cure efforts, with particular emphasis on epitope specificity. Recent studies have demonstrated that successful in vivo containment of the virus is rooted in the specific targeting of fitness-constrained, mutation-resistant regions of the HIV proteome. We highlight these new insights, providing context with previous observations in HIV and other models of viral control, and delineate their translation into a therapeutic vaccine.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kaseke C, Tano-Menka R, Senjobe F, et al. The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts. J Infect Dis. 2021. PMID: 33586771. doi:10.1093/infdis/jiaa333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。